![](https://webarchive.library.unt.edu/eot2008/20081017104435im_/http://www.cancer.gov/images/spacer.gif) |
|
Phase II Study of Lobradimil and Carboplatin in Patients With Recurrent or Refractory Childhood Brain Tumors
Alternate Title Basic Trial Information Objectives Entry Criteria Expected Enrollment Outline Published Results Related Publications Trial Contact Information Registry Information
Alternate Title
Lobradimil and Carboplatin in Treating Children With Brain Tumors
Basic Trial Information
![](https://webarchive.library.unt.edu/eot2008/20081017104435im_/http://www.cancer.gov/images/spacer.gif) |
Phase
![](https://webarchive.library.unt.edu/eot2008/20081017104435im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081017104435im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081017104435im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081017104435im_/http://www.cancer.gov/images/spacer.gif) |
Type
![](https://webarchive.library.unt.edu/eot2008/20081017104435im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081017104435im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081017104435im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081017104435im_/http://www.cancer.gov/images/spacer.gif) |
Status
![](https://webarchive.library.unt.edu/eot2008/20081017104435im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081017104435im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081017104435im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081017104435im_/http://www.cancer.gov/images/spacer.gif) |
Age
![](https://webarchive.library.unt.edu/eot2008/20081017104435im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081017104435im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081017104435im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081017104435im_/http://www.cancer.gov/images/spacer.gif) |
Sponsor
![](https://webarchive.library.unt.edu/eot2008/20081017104435im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081017104435im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081017104435im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081017104435im_/http://www.cancer.gov/images/spacer.gif) |
Protocol IDs
![](https://webarchive.library.unt.edu/eot2008/20081017104435im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081017104435im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081017104435im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081017104435im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081017104435im_/http://www.cancer.gov/images/spacer.gif)
Phase II
![](https://webarchive.library.unt.edu/eot2008/20081017104435im_/http://www.cancer.gov/images/spacer.gif)
|
![](https://webarchive.library.unt.edu/eot2008/20081017104435im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081017104435im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081017104435im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081017104435im_/http://www.cancer.gov/images/spacer.gif)
Treatment
![](https://webarchive.library.unt.edu/eot2008/20081017104435im_/http://www.cancer.gov/images/spacer.gif)
|
![](https://webarchive.library.unt.edu/eot2008/20081017104435im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081017104435im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081017104435im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081017104435im_/http://www.cancer.gov/images/spacer.gif)
Completed
![](https://webarchive.library.unt.edu/eot2008/20081017104435im_/http://www.cancer.gov/images/spacer.gif)
|
![](https://webarchive.library.unt.edu/eot2008/20081017104435im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081017104435im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081017104435im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081017104435im_/http://www.cancer.gov/images/spacer.gif)
21 and under at diagnosis
![](https://webarchive.library.unt.edu/eot2008/20081017104435im_/http://www.cancer.gov/images/spacer.gif)
|
![](https://webarchive.library.unt.edu/eot2008/20081017104435im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081017104435im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081017104435im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081017104435im_/http://www.cancer.gov/images/spacer.gif)
NCI
![](https://webarchive.library.unt.edu/eot2008/20081017104435im_/http://www.cancer.gov/images/spacer.gif)
|
![](https://webarchive.library.unt.edu/eot2008/20081017104435im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081017104435im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081017104435im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081017104435im_/http://www.cancer.gov/images/spacer.gif)
NCI-98-C-0074H CCG-09716, ALK-01-041, NCI-T98-0011, COG-C09716, T98-0011, NCT00019422
![](https://webarchive.library.unt.edu/eot2008/20081017104435im_/http://www.cancer.gov/images/spacer.gif)
|
![](https://webarchive.library.unt.edu/eot2008/20081017104435im_/http://www.cancer.gov/images/spacer.gif) |
|
Objectives - Determine the objective response rate in patients with recurrent or refractory childhood brain tumors treated with lobradimil and carboplatin.
- Determine the time to progression in patients treated with this regimen.
- Assess the toxicity of this regimen in this patient population.
- Determine the quality of life of patients treated with this regimen.
Entry Criteria Disease Characteristics:
- Histologically confirmed childhood brain tumor that is recurrent or
refractory
or for which no standard chemotherapy exists
- High-grade glioma (anaplastic astrocytoma or
glioblastoma multiforme) (High-grade glioma stratum closed to accrual as of
01/08/2002)
- Low-grade glioma
- Medulloblastoma/primitive neuroectodermal tumor (PNET)
- Ependymoma
- Brainstem tumor or visual pathway glioma (with
radiographic evidence only)
(Brainstem glioma stratum closed to accrual as of
12/21/2000)
- Evidence of recurrent or progressive disease after front-line therapy
documented as an increase in tumor size or appearance of new lesion(s)
on MRI
- Patients who did not previously receive radiotherapy as front-line
therapy are
eligible at time of second recurrence if the first recurrence was
treated with
radiotherapy only
- Measurable disease in at least 2 dimensions by MRI
- Diffuse meningeal involvement not considered
measurable if it is the only site of disease
- Disease must not be limited to the meninges
- No metastases outside of the CNS
Prior/Concurrent Therapy:
Biologic therapy: - At least 72 hours since filgrastim (G-CSF)
- No concurrent biologic therapy for brain tumor
Chemotherapy: - See Disease Characteristics
- No prior carboplatin or lobradimil
- No more than 1 prior chemotherapy regimen for high-grade
glioma, low-grade glioma, or ependymoma
- No more than 2 prior chemotherapy regimens for
medulloblastoma/PNET
- At least 4 weeks since prior nitrosoureas (2 weeks if also
received stem cell/bone marrow rescue)
- At least 2 weeks since any other prior myelosuppressive
chemotherapy and recovered
- No other concurrent chemotherapy for brain tumor
Endocrine therapy: - Concurrent corticosteroids for management of tumor-related
edema allowed
Radiotherapy: - See Disease Characteristics
- At least 6 weeks since prior radiotherapy to measurable
disease and recovered
- No concurrent radiotherapy for brain tumor
Surgery: - No concurrent surgery except for ventriculo-peritoneal shunt
placement or revision
Other: - At least 24 hours since prior vasodilating agents,
angiotensin-converting enzyme inhibitors, calcium channel blockers, or
beta-blockers
Patient Characteristics:
Age: - 21 and under at diagnosis
Performance status: Life expectancy: Hematopoietic: - Absolute granulocyte count at least 1,000/mm3
- Hemoglobin at least 8.0 g/dL (transfusion allowed)
- Platelet count at least 100,000/mm3
Hepatic: - Bilirubin less than 1.5 times upper limit of normal
(ULN)
- SGPT no greater than 2.5 times ULN
- No significant hepatic illness
Renal: - Creatinine within limits as defined below by age:
- Age 5 and under: less than 1.2 mg/dL
- Age 6 to 10: less than 1.5 mg/dL
- Age 11 to 15: less than 1.8 mg/dL
- Age 16 and over: less than 2.4 mg/dL
Cardiovascular: - No significant cardiac illness
Pulmonary: - No significant pulmonary illness
Other: - No significant systemic illness or organ dysfunction that
would preclude study
- No allergic reaction to platinum-containing
compounds
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
Expected Enrollment A maximum of 146 patients will be accrued for this study within 2-4 years. Outline This is a multicenter study. Patients are stratified according to histology (high-grade glioma vs
low-grade glioma vs brainstem or visual pathway glioma vs
medulloblastoma/primitive neuroectodermal tumor vs ependymoma). (Brainstem
glioma stratum closed to accrual as of 12/21/2000.) (High-grade glioma
stratum closed to accrual as of 01/08/2002.) Patients receive carboplatin IV over 15 minutes and lobradimil IV over
10 minutes on days 1 and 2. Treatment repeats every 4 weeks for up to 12
courses in the absence of disease progression or unacceptable toxicity. After
completion of course 12, patients may receive additional courses at the
discretion of the institutional investigator. Quality of life is assessed at baseline and then every 3 courses. Patients are followed every 3 months for 1 year or until evidence of
disease progression or initiation of a new therapy. Published ResultsWarren K, Jakacki R, Widemann B, et al.: Phase II trial of intravenous lobradimil and carboplatin in childhood brain tumors: a report from the Children's Oncology Group. Cancer Chemother Pharmacol 58 (3): 343-7, 2006.[PUBMED Abstract] Related PublicationsWarren KE, Patel MC, Aikin AA, et al.: Phase I trial of lobradimil (RMP-7) and carboplatin in children with brain tumors. Cancer Chemother Pharmacol 48 (4): 275-82, 2001.[PUBMED Abstract] Warren KE, Patel MC, Adamson PC, et al.: Phase I trial of RMP-7 and carboplatin in pediatric patients with brain tumors. [Abstract] Proceedings of the American Society of Clinical Oncology 17: A-764, 1998.
Trial Contact Information
Trial Lead Organizations NCI - Center for Cancer Research ![](https://webarchive.library.unt.edu/eot2008/20081017104435im_/http://www.cancer.gov/images/spacer.gif) | ![](https://webarchive.library.unt.edu/eot2008/20081017104435im_/http://www.cancer.gov/images/spacer.gif) | ![](https://webarchive.library.unt.edu/eot2008/20081017104435im_/http://www.cancer.gov/images/spacer.gif) | Katherine Warren, MD, Protocol chair | ![](https://webarchive.library.unt.edu/eot2008/20081017104435im_/http://www.cancer.gov/images/spacer.gif) | | ![](https://webarchive.library.unt.edu/eot2008/20081017104435im_/http://www.cancer.gov/images/spacer.gif) |
Children's Oncology Group ![](https://webarchive.library.unt.edu/eot2008/20081017104435im_/http://www.cancer.gov/images/spacer.gif) | ![](https://webarchive.library.unt.edu/eot2008/20081017104435im_/http://www.cancer.gov/images/spacer.gif) | ![](https://webarchive.library.unt.edu/eot2008/20081017104435im_/http://www.cancer.gov/images/spacer.gif) | Regina Jakacki, MD, Protocol chair | ![](https://webarchive.library.unt.edu/eot2008/20081017104435im_/http://www.cancer.gov/images/spacer.gif) | | ![](https://webarchive.library.unt.edu/eot2008/20081017104435im_/http://www.cancer.gov/images/spacer.gif) |
Registry Information | ![](https://webarchive.library.unt.edu/eot2008/20081017104435im_/http://www.cancer.gov/images/spacer.gif) | Official Title | | A Phase II Trial of Intravenous Cereport (RMP-7) and Carboplatin in Childhood Brain Tumors | ![](https://webarchive.library.unt.edu/eot2008/20081017104435im_/http://www.cancer.gov/images/spacer.gif) | Trial Start Date | | 1998-03-02 | ![](https://webarchive.library.unt.edu/eot2008/20081017104435im_/http://www.cancer.gov/images/spacer.gif) | Registered in ClinicalTrials.gov | | NCT00019422 | ![](https://webarchive.library.unt.edu/eot2008/20081017104435im_/http://www.cancer.gov/images/spacer.gif) | Date Submitted to PDQ | | 1998-03-17 | ![](https://webarchive.library.unt.edu/eot2008/20081017104435im_/http://www.cancer.gov/images/spacer.gif) | Information Last Verified | | 2003-04-02 | ![](https://webarchive.library.unt.edu/eot2008/20081017104435im_/http://www.cancer.gov/images/spacer.gif) | NCI Grant/Contract Number | | CA13539 |
Note: The purpose of most clinical trials listed in this database is to test new cancer treatments, or new methods of diagnosing, screening, or preventing cancer. Because all potentially harmful side effects are not known before a trial is conducted, dose and schedule modifications may be required for participants if they develop side effects from the treatment or test. The therapy or test described in this clinical trial is intended for use by clinical oncologists in carefully structured settings, and may not prove to be more effective than standard treatment. A responsible investigator associated with this clinical trial should be consulted before using this protocol. Back to Top |
![](images/spacer.gif) |